Dr. Abbey Doses First Patient in Phase III LUGANO Clinical Trial of Duravyu for Wet AMD
Texas Retina Associates Director of Clinical Research for Dallas Ashkan Abbey, MD, recently dosed the first patient in the Phase III LUGANO clinical trial of Duravyu (formerly EYP-1901) for the treatment of
read more
Dr. Abbey Participated in Roundtable Discussion on Newer Therapies for Wet AMD and Diabetic Macular Edema
Texas Retina’s Ashkan Abbey, MD, recently participated in a roundtable discussion on “Navigating Wet AMD and DME Using Newer Therapies” available on Eyetube. Dr. Abbey and fellow panelist Scott Walter, MD, MSc,
read more
Dr. Abbey Presented 2.5 Year Results of the TRUCKEE Study at The Retina Society Annual Meeting
Texas Retina’s Ashkan M. Abbey, MD, presented “The Real-World Efficacy and Safety of Faricimab in Neovascular Age-Related Macular Degeneration: The TRUCKEE Study – 2.5 Year Results” at the 57thAnnual Scientific Meeting of
read more
New Clinical Trials Available at Texas Retina
At Texas Retina, we remain committed to conducting ongoing research that will advance retinal care. That is why for over 20 years, for physicians have participated in more than 100 national clinical
read more New Clinical Trials at Texas Retina
Over the past two decades, Texas Retina physicians have participated in more than 100 national clinical trials, offering our patients access to promising new treatments for a variety of retina conditions, including
read more
Dr. Abbey Presented Key Results of DAVIO 2 Clinical Trial for Wet AMD at Retina World Congress
At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu),
read more
Three New Clinical Trials Available at Texas Retina
Medical researchers continue to make significant advances in the diagnosis and treatment of retinal conditions, and our physicians remain committed to participating in clinical trials that will improve care for our patients.
read more New Treatment for Wet AMD and Diabetic Eye Disease Reduces Treatment Burden for Patients by Extending Dosing Intervals
On August 18, 2023, the U.S. Food and Drug Administration (FDA) approved Eylea HD (aflibercept), a high-dose version of Eylea, for the treatment of several retinal conditions, including advanced neovascular age-related macular
read more New Clinical Trials Available at Texas Retina
Our physicians remain committed to participating in ongoing retina research, providing our patients with access to promising new treatments through clinical trials. In fact, our research program has grown to become one
read more
Dr. Abbey Presents Phase 1 DAVIO Clinical Trial Results to the Association for Research in Vision and Ophthalmology
Dr. Abbey presented the results from the Phase 1 DAVIO trial at ARVO 2023, the annual meeting of the Association for Research in Vision and Ophthalmology (ARVO). The trial was a first-in-human
read more